Alignment Healthcare CEO sells 298K shares

Alignment Healthcare, Inc. CEO and director John E. Kao reported open-market sales of 298,000 shares of common stock on July 10, 2026.

Accepted by SEC EDGAR 07/14/2026 - 04:47 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Alignment Healthcare, Inc. CEO and director John E. Kao reported open-market sales of 298,000 shares of common stock on July 10, 2026. The shares were sold in multiple transactions at weighted-average prices of $19.8122 and $20.6471 per share under a Rule 10b5-1 trading plan adopted on November 21, 2025, and include sales from a trust for which Mr. Kao serves as trustee.

Insider Trade Summary 10b5-1

Net Seller: 298,000 shares

Net Sell 2 txns

Insider KAO JOHN E

Role Chief Executive Officer

Sold 298,000 shs ($5.92M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	279,644	$19.8122	$5.54M
Sale	Common Stock F1, F4, F3	18,356	$20.6471	$379K
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,088,766 shares (Indirect, See Footnote); Common Stock — 1,608,743 shares (Direct)

Footnotes (4)

1. F1. Date of Rule 10b5-1 plan adoption: 11/21/2025
2. F2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $19.55 to $20.54. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
3. F3. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.
4. F4. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $20.55 to $20.84. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Key Figures

Shares sold: 298,000 shares Tranche 1 shares: 18,356 shares Tranche 2 shares: 279,644 shares +3 more

6 metrics

Shares sold 298,000 shares Aggregate common shares sold on July 10, 2026

Tranche 1 shares 18,356 shares Common stock sold in first reported transaction on July 10, 2026

Tranche 2 shares 279,644 shares Common stock sold in second reported transaction on July 10, 2026

Weighted-average price tranche 1 $20.6471 per share Price for the 18,356-share open-market sale

Weighted-average price tranche 2 $19.8122 per share Price for the 279,644-share open-market sale

Rule 10b5-1 plan adoption date November 21, 2025 Date the trading plan governing these sales was adopted

Key Terms

Rule 10b5-1 plan, weighted-average price, open-market sale, indirect ownership, +1 more

5 terms

Rule 10b5-1 plan regulatory

"Date of Rule 10b5-1 plan adoption: 11/21/2025"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted-average price financial

"The reported price in column 4 is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

open-market sale market

"Transaction_action is recorded as an open-market sale of common stock."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"The "I" code in direct_or_indirect indicates indirect ownership through an entity."

trustee financial

"Represents securities held by JEK Trust, of which Mr. Kao is the trustee."

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Alignment Healthcare (ALHC) report for CEO John E. Kao?

Alignment Healthcare (ALHC) reported that CEO John E. Kao sold 298,000 shares of common stock on July 10, 2026. The filing shows two open-market sale transactions executed under a pre-established Rule 10b5-1 trading plan rather than discretionary same-day decisions.

How many ALHC shares did John E. Kao sell in each transaction on July 10, 2026?

John E. Kao sold 18,356 shares in one transaction and 279,644 shares in another on July 10, 2026. Both transactions involved Alignment Healthcare common stock and are categorized as non-derivative open-market sales in the Form 4 filing.

At what prices were the Alignment Healthcare (ALHC) shares sold by the CEO?

The reported weighted-average sale prices were $20.6471 and $19.8122 per share for the two transactions. Footnotes explain that actual individual sale prices ranged between $19.55 and $20.84 across multiple trades within each reported transaction.

Were John E. Kao’s ALHC stock sales made under a Rule 10b5-1 trading plan?

Yes. A footnote states that the Rule 10b5-1 trading plan governing these sales was adopted on November 21, 2025. Such plans allow pre-scheduled transactions, indicating the timing of these July 10, 2026 sales was set in advance rather than decided opportunistically.

What type of ownership was involved in the CEO’s ALHC share sales?

The sales are reported as indirect ownership transactions, with a footnote stating the securities are held by the JEK Trust. Mr. Kao is identified as trustee of this trust, meaning the reported sales occurred through that entity rather than solely from his direct personal holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAO JOHN E

(Last) (First) (Middle)

1100 W. TOWN & COUNTRY RD., SUITE 1600

(Street)

ORANGE CALIFORNIA 92868

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2026		S(1)		279,644	D	$19.8122(2)	1,107,122	I	See Footnote(3)
Common Stock	07/10/2026		S(1)		18,356	D	$20.6471(4)	1,088,766	I	See Footnote(3)
Common Stock								1,608,743	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 11/21/2025

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $19.55 to $20.54. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

3. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

4. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $20.55 to $20.84. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)